| Literature DB >> 30506673 |
Lang Li1, Tammy Sajdyk2, Ellen M L Smith3, Chien Wei Chang1, Claire Li4, Richard H Ho5, Raymond Hutchinson3, Elizabeth Wells6, Jodi L Skiles2, Naomi Winick7, Paul L Martin8, Jamie L Renbarger2.
Abstract
Vincristine is one of the core chemotherapy agents used in the treatment of pediatric acute lymphoblastic leukemia (ALL). However, one of the major toxicities resulting from vincristine exposure is vincristine-induced peripheral neuropathy (VIPN). When VIPN results in significant morbidity, the vincristine dose may need to be reduced, thus potentially decreasing the effectiveness of treatment. To date, there are no robust biomarkers used clinically to determine which patients will be at risk for worse neuropathy. The current study included genomewide association study (GWAS) in two independent cohorts: Pediatric Oncology Group (POG) ALL trials and a multicenter study based at Indiana University in children with ALL. A meta-analysis of the cohorts identified two single-nucleotide polymorphisms (SNPs), rs1045644 and rs7963521, as being significantly (P value threshold 0.05/4749 = 1.05E-05) associated with neuropathy. Subsequently these SNPs may be effective biomarkers of VIPN in children with ALL.Entities:
Mesh：
Substances：
Year: 2019 PMID： 30506673 PMCID： PMC6513686 DOI： 10.1002/cpt.1324
Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875